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ABSTRACT The afi T-cell receptor (TCR) recognizes
antigenic peptides bound to major histocompatibility complex
(MHC) molecules. In contrast to the antibody combining site,
for which the antigen contact or complementarity-determining
residues (CDRs) have been precisely defined, the location and
function of the corresponding CDR regions of the a and (3 TCR
chains are not known. To develop a model system for system-
atic analysis of the CDRs of the af TCR, we isolated a panel
of murine T-cell clones that recognize a lysozyme peptide
containing residues 74-88 bound to either A" or Abt-I2 MHC
class II molecules. Although these twoMHC molecules differ by
only three amino acid residues within the AP chain, each of the
T-cell clones was specific for peptide bound to the self-MHC
molecule and did not rpcognize the same peptide bound to the
other MHC molecule. The structural basis for this exquisite
ligand specificity of the TCRs was analyzed by isolation and
characterization of a and (3 chain genes from five closely
related T-cell clones. Comparison of predicted amino acid
sequences mapped the ligand specificity differences to residues
present within the a chain variable region segment and the a
and (3 chain variable-joining region junction regions. Thus
with current models of TCR-ligand interactions, the results
suggest that residues 26-30 of the a chain variable region may
constitute one of the CDR regions of the TCR.
The unique ligand specificity of the T-cell receptor (TCR) for
peptides bound to major histocompatibility complex (MHC)
molecules is the basis for selection of self-MHC-restricted T
cells in the thymus and for MHC-restricted antigen recogni-
tion by mature T cells (1-3). Comparison of the a and f TCR
chains with their antibody heavy and light chain counterparts
has revealed similarities in genomic organization of gene
segments encoding these polypeptides, in genetic mecha-
nisms that give rise to structural diversity, and in conserva-
tion of many amino acid residues at identical positions (4, 5).
These common features suggest that the TCR and the anti-
body combining sites are closely related in structure and
function. However, unlike the antibody molecule, the TCR
does not directly bind to the antigen and its ligand combining
site is likely to contact residues ofboth antigenic peptides and
the MHC molecule. The precise location of these comple-
mentarity-determining residues (CDRs) of the TCR is not
known.
Direct gene transfer studies as well as comparison of
primary amino acid sequences ofa and l3 chains derived from
TCRs with defined antigenic specificities have suggested that
variable (V) regions of both chains contribute to ligand
specificity (for review, see ref. 6). Several exceptions are
known, however, where ligand specificity strongly correlates
with the utilization of a particular TCR l3 chain V region (V13)
and, occasionally, of a chain V region (Va) segments (7-12).
An essentially similar model has been proposed indepen-
dently by Davis and Bjorkman (13) and by Chothia et al. (5)
to explain the structural relationship between the af TCR
combining site with the antigen-MHC ligand recognition
function. This model was prompted by solution of the crystal
structure of the class I MHC molecule that revealed the
location of the polymorphic residues within the MHC mol-
ecules as lining the antigen binding groove on the top surface
of the molecule (14). By extrapolating the known structure of
the antigen combining site of antibody molecules to the TCR
combining site, the model suggests that residues within the V
segments contact the MHC and residues within the CDR3
regions contact the antigen. Whereas changes in the ligand
specificity ofTCRs do correlate with amino acid substitutions
within the V(D)J regions (where D is diversity and J isjoining)
of the a and f3 chains, the role of the Va/V/ segments and of
the MHC molecules in determining these effects is not known
(6, 15).
In this report, we describe the development of a model
system to systematically test the structure-function relation-
ship of the af3 TCR. We have generated a panel of T-cell
clones that are specific for lysozyme peptides bound to either
the Ab or the Abm-12 class II MHC molecules. These two
MHC molecules differ only in three amino acids at positions
67, 70, and 71 of their AP3 subunits (16). We have identified
minimal peptide determinants recognized by these TCRs and
have determined the sequences offive pairs of closely related
Va and VP3 regions.t Comparison among these sequences
demonstrates that differences in TCR ligand specificity cor-
relate with amino acid substitutions within the Va segment
and within the Va-Ja and V1-J13 junction regions.
MATERIALS AND METHODS
Animals and Peptides. C57BL/6 (B6, Ab) and B6-C-H-
2bm-12 (bm-12, Abm-12) mice were obtained from The Jackson
Laboratory. Mice of age 2-12 months old of either sex were
used. Mice were immunized with 7 nmol of synthetic peptides
in complete Freund's adjuvant (17). Hen egg white lysozyme
peptides corresponding to residues 74-96 (p74-96), NH2-
Asn-Leu-Cys-Asn-Ile-Pro-Cys-Ser-Ala-Leu-Leu-Ser-Ser-
Asp-Ile-Thr-Ala-Ser-Val-Asn-Cys-Ala-Lys-OH were pre-
pared by solid-phase synthesis (17).
Cell Culture. Methods for generation and maintenance of
antigen-specific long-term T-cell lines or T-cell hybrids have
been described (17). Mouse L-cell fibroblasts expressing the
Ab (FT7.1) or the Abm-12 (FT7.2) MHC molecules (18) were
kindly provided by F. Ronchese and R. Germain.
Abbreviations: APC, antigen-presenting cell; CDR, complementar-
ity-determining residue; MHC, major histocompatibility complex;
TCR, T-cell receptor; V, D, J, and C, variable, diversity, joining, and
constant, respectively; Va, JB, etc., a chain V region, (3 chain J
region, etc.; IL-2, interleukin 2; p(74-96), p(74-90), etc., lysozyme
peptides containing residues 74-96, 74-90, etc.
tThe sequences reported in this paper have been deposited in the
GenBank data base (accession nos. M87844-M87853).
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Specificity Assays. T-cell specificity assays were carried out
as described (17). Briefly, 1 x 104 long-term T cells or 1 x 105
T-cell hybrids were cocultured with antigen-presenting cells
(APCs) in the presence of medium alone or the indicated
peptides at 7 ,uM in 0.2 ml in 96-well tissue culture plates.
APCs were either 5 x 105 syngeneic spleen cells treated with
mitomycin C (Sigma, 50 ,ug/ml) at 37°C for 30 min or 1 x 105
untreated L-cell transfectants. The specific T-cell response of
lymph node cells or long-term T-cell lines was determined by
incorporation of [3H]thymidine (Amersham) directly into
proliferating T cells. For T-cell hybrids, 50 ,ul of supernatant
from 18- to 24-h cultures was tested for interleukin 2 (IL-2) by
using a secondary culture containing the IL-2-dependent cell
line HT-2 (17).
Isolation and Sequence Analysis of TCR and a Chain
Genes. DNA rearrangements encoding the functional
VDJ3--C, (where Cf3 is /3 chain constant region) chains were
identified as either EcoRI or HindIII fragments by Southern
blot analysis ofDNA isolated from the T-cell hybrids (19) and
cloned with size-selected DNA (including the rearranged
fragment) isolated from agarose gels as described (20). The
isolated clones were subjected to restriction enzyme analysis
and appropriate fragments containing the VDJB sequences
were subcloned into M13mpl8 vector and sequenced by the
dideoxynucleotide chain-termination method (21). Specific
J,/ oligonucleotide primers and the universal M13 vector
primer were used to sequence both strands of the clones.
Total cellular RNA was prepared from the T-cell hybrids
and poly(A)+ RNA was isolated by two passes over oli-
go(dT)-cellulose (Collaborative Research, type 3). cDNA
was synthesized from the poly(A)' RNA using avian myelo-
blastosis virus reverse transcriptase, RNase H, and Esche-
richia coli DNA polymerase I as described (22). The cDNA
fragments >1 kilobase were inserted into the AgtlO vector
after addition of EcoRI linkers. The cDNA libraries were
screened with murine Ca and C,3 probes, and positive clones
were probed with Val and V,31 DNA fragments to eliminate
clones derived from the BW5147 fusion partner (23, 24). The
EcoRI inserts of the AgtlO cDNA clones were isolated,
subcloned into M13mpl8 vector, and sequenced as for,
chain genes above with oligonucleotides specific for the 5'
ends of Ca or CB and the universal M13 primers (23, 24).
RESULTS AND DISCUSSION
Responsiveness of bm-12 Mice to p74-96. In our earlier
studies with p74-96-specific T cells in C57BL/6 (B6) mice,
two distinct lysozyme peptides containing residues 74-90
(p74-90) and 81-96 (p81-96) were identified as the major
antigenic determinants recognized in the context of the A"
MHC molecule (25, 26). B6-C-H-2bm-12 (bm-12) mice express
the Abm-12 MHC molecule, which differs from the Ab MHC
molecule in only three amino acid residues at positions 67,70,
and 71 of the Af3 chain. To assess the influence of the amino
acid differences among Abm-12 and Ab molecules toward the
antigen-specific T-cell response, bm-12 mice were immu-
nized with p74-96. The antigen-specific proliferative re-
sponse ofdraining lymph node cells and long-term T-cell lines
derived from the B6 and bm-12 mice was tested with the
immunogen and with smaller peptides (Table 1). Similar to B6
T cells, bm-12 T cells responded strongly to p74-96 and to
p74-90. Furthermore, the minimal peptide determinant rec-
ognized by both B6 and bm-12 mice within p74-90 was similar
in that truncation of the four C-terminal residues 87-90 in
p74-86 abolished the antigen-specific response. However,
unlike B6 mice, which also elicited T cells specific for p81-96,
T cells with this specificity were not detected in bm-12 mice.
Thus, the three amino acid substitutions between the two
class IIMHC molecules did not alter the ability ofbm-12 mice
to respond to the p74-90 but were, however, associated with
the absence of p81-96-specific T cells in bm-12 mice.
Both B6 and bm-12 T-Cell Clones Recognize Similar Mini-
mal Peptide Determinants. The finding that T cells with
similar antigen specificity were induced in both B6 and bm-12
mice is in marked contrast to our earlier studies (17). Com-
parison of T-cell responses induced by p74-96 had shown
dramatic differences in the minimal peptide determinants
recognized in the context of Ak (p74-82) or Ek (p85-96) class
II MHC molecules. These differences were attributed to the
extensive structural differences between the polymorphic
MHC molecules (17). To identify possible differences in the
minimal peptide determinant(s) within p74-90 recognized by
individual B6 and bm-12 T cells, additional synthetic peptides
were tested with individual T-cell clones. Each of the four B6
and five bm-12 T-cell hybrids recognized p74-90, p74-89,
and p74-88, demonstrating that the minimal antigenic deter-
minants were contained within p74-88 (Table 2). Because
each of the clones failed to recognize p74-86, residues 87
and/or 88 were required for antigen recognition. The require-
ment for both residues 87 and 88 was, however, not absolute
because B04T27.6, bmlT5.1, and bm4T17.2 T cells could
also recognize p74-87. Furthermore, truncation of a single
amino acid from the N-terminal end (p75-96) completely
abolished peptide recognition by either B6 or bm-12 T-cell
clones (data not shown). Thus, in contrast to the nonover-
lapping peptides p74-82 vs. p85-96, which were presented
Table 1. Response of B6 and bm-12 mice to p74-96
[3H]Thymidine incorporation per culture, Acpm x 10-3
Cells Medium p74-96 p74-90 p74-86 p81-96
B6 LNC (1.0 ± 0.1) 83.7 ± 3.8 ND 0.7 ± 0.9 34.8 ± 4.9
B6 LNC (7.0 ± 0.3) 127.0 ± 6.4 70.5 ± 2.1 1.7 ± 3.1 24.3 ± 6.3
BO4T (5.5 ± 4.2) 65.9 ± 1.8 84.6 ± 3.4 0.2 ± 2.9 57.8 + 3.4
bm-12 LNC (1.7 ± 0.2) 54.3 ± 6.8 ND 4.1 ± 3.9 0.5 ± 0.6
bm-12 LNC (10.1 ± 3.8) 89.8 ± 4.6 40.3 ± 2.3 1.2 ± 0.8 2.3 + 1.0
bmlT (0.7 ± 0.3) 48.6 ± 2.1 82.6 ± 3.0 ND 0.5 + 0.0
bm2T (0.9 ± 0.0) 200.9 ± 7.2 269.1 ± 18.6 ND 0.3 ± 0.1
Lymph node cells (LNCs) were obtained from either B6 or bm-12 mice (pool of three animals)
immunized 10 days earlier with p74-96. BO4T, bmlT, and bm2T are bulk cultures of long-term T-cell
lines established from B6 (BO4T) or bm-12 (bmlT and bm2T) mice. Approximately 4 x 105 LNCs alone
or 1 x 104 T cells plus 5 x 105 mitomycin C-treated normal syngeneic spleen cells were cultured in
triplicate for 4 days in medium alone or with the indicated peptides at 7 ,uM. Incorporation during the
final 18-h incubation of cultures pulse-labeled with 1 ttCi of [3H]thymidine is shown (1 Ci = 37 GBq);
data are mean ± SD. Background cpm with medium alone are shown in parentheses and have been
subtracted to show antigen-specific cpm. Boldface type emphasizes positive responses. ND, not
determined.
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Table 2. Minimal peptide determinants recognized by p74-96-specific B6 and bm-12 T-cell clones
[3H]Thymidine incorporation per culture, Acpm x 10-3
T cells Medium p74-90 p74-89 p74-88 p74-87 p74-86
B04H9.1 (1.9 ± 0.3) 93.0 ± 5.1 69.8 ± 2.2 38.8 ± 1.0 1.7 ± 0.4 0.1 ± 0.0
BO3H.25 (1.8 ± 0.1) 9.2 ± 0.2 6.8 ± 1.8 10.6 ± 2.0 3.1 ± 0.2 0.2 ± 0.1
B04T8.3 (8.5 ± 0.5) 44.1 ± 8.3 82.2 ± 4.5 35.7 ± 2.4 0.2 ± 1.5 0.1 ± 0.6
B04T27.6 (1.0 ± 0.1) 80.1 ± 2.1 68.7 ± 4.1 53.4 ± 7.7 43.7 ± 0.9 2.1 ± 1.0
bm2T3.1 (10.8 ± 1.5) 55.4 :± 2.6 59.3 ± 4.2 38.2 ± 3.1 7.3 ± 1.1 1.4 ± 0.6
bm4T6.2 (1.1 ± 0.3) 64.0 ± 4.8 89.1 ± 5.0 55.0 ± 1.4 2.6 ± 1.3 ND
bmlT7.6 (3.9 ± 0.8) 194.8 ± 0.8 125.6 ± 18.2 86.0 ± 3.0 6.5 ± 1.2 0.3 ± 1.1
bmlTS.1 (1.5 ± 0.4) 80.9 ± 2.8 76.1 ± 6.2 81.7 ± 4.6 92.2 ± 4.2 0.5 ± 0.2
bm4T17.2 (1.1 ± 0.3) 36.0 ± 0.8 40.1 ± 3.6 66.1 ± 2.1 70.9 ± 3.6 2.1 ± 1.1
Prefix B or bm indicates the B6 or bm-12 origin of T-cell hybrids. Cells were tested with parental
spleen cells of the appropriate strain. T cells (1 x 101 cells) were cultured with 5 x 105 mitomycin
C-treated normal B6 or bm-12 spleen cells in medium alone or with the indicated peptides at 7 1tM. After
24 h, culture supernatants were tested for presence of IL-2 in a secondary culture with the
IL-2-dependent HT-2 cells. Incorporation in HT-2 cells pulse-labeled with [3H]thymidine at 1 ,uCi per
culture during the final 4 h of an 18-h culture is shown. Other details are as in Table 1.
exclusively by Ak and Ek molecules (17), the Ab and Abm-12
MHC molecules apparently presented the same p74-88 to T
cells.
The B6 and bm-12 TCRs Distinguish Between the Pep-
tideAb or -Abm-12 Complexes. The close similarity in struc-
tures of the Ab and Abm-12 class II MHC molecules and in the
peptide specificity of the B6 and bm-12 T cells suggested that
these TCRs may cross-react with either antigen-MHC com-
plex. To assess this possibility, we tested the ability ofAb and
Abm-12 APCs to stimulate T cells with the same antigen. For
this experiment, mouse L cells that had been transfected with
the Aab and either A/3b (FI7.1) or Afbm-12 (FT7.2) genes were
used as APCs (18). The data in Table 3 demonstrate that each
of these T cells recognized antigen presented only by self Ab
or Abm-12 molecules. Thus, the TCRs expressed by these T
cells, despite their similar antigen specificity, clearly distin-
guish between the two class II MHC molecules.
The three amino acid substitutions between the Ab and
Abm-l2 are located within one of the two top a-helices in the
hypothetical model of the class II MHC molecule (27). In this
location, one or more of the side chains could directly affect
interactions of the MHC molecules with the peptides and/or
with the TCR. The absence of p81-96-specific T cells in
bm-12, but not in B6 mice (Table 1), could be due to the
inability of this peptide to bind to the Abm-12 molecule.
Table 3. B6 and bm-12 T cells recognize antigen only with
self-MHC molecules
[3H]Thymidine incorporation per culture,
Acpm x 10-3
cells/ FT7.1 (Ab) FT7.2 (Abm-12)
APCs Medium Antigen Medium Antigen
B04H9.1 (10.6 ± 1.0) 117.9 t 6.4 (1.8 ± 0.6) 0.8 ± 0.8
BO3H.25 (0.4 ± 0.1) 6.8 ± 0.2 (1.1 ± 1.0) 0.2 ± 0.1
B04T27.6 (0.6 ± 0.0) 86.8 ± 9.0 (0.8 ± 0.1) 0.2 ± 0.1
B04T8.3 (6.6 ± 1.6) 11.6 ± 1.2 (1.6 ± 2.5) 0.1 ± 0.7
bm2T3.1 (1.9 ± 0.5) 0.3 ± 0.4 (1.8 ± 0.6) 39.5 ± 0.7
bm4T6.2 (1.8 ± 0.1) 0.8 ± 0.1 (1.6 ± 0.2) 13.2 ± 0.1
bmlTS.1 (7.6 ± 0.6) 0.8 ± 0.6 (6.4 ± 0.4) 86.7 ± 1.0
bmlT7.6 (2.4 ± 2.9) 0.9 ± 3.1 (1.7 ± 4.8) 44.1 ± 1.6
bm4T17.2 (1.1 ± 0.1) 0.1 ± 0.1 (1.3 ± 0.2) 23.6 ± 2.4
Culture conditions were identical to those described in Table 2,
except that 1 x 105 FT7.1 or Ff7.2 L cells expressing the Ab or Abm-12
class II MHC molecules were used as APCs instead of normal spleen
cells. The response to antigen was tested at 7 ,uM p74-9S. Other
details are as in Table 1.
Alternatively, the absence of p81-96-specific T cells could be
due to an influence of these three residues on positive or
negative selection of self-MHC reactive TCRs in the thymus
(3). Nevertheless, existence ofp74-88-specific T cells in both
B6 and bm-12 mice demonstrates that both Ab and Abm-12
molecules can both bind to the same peptide. Furthermore,
the fact that each of the two sets ofTCRs fails to cross-react
between the peptide-bound Ab and Abm-12 molecules shows
that these three residues do affect TCR-MHC interactions.
The simplest interpretation of these results is that, for TCRs
specific for p74-88, the interactions between the TCR and
MHC include contacts with one or more of the three amino
acid substitutions. However, more complex interpretations
in which the lack of cross-reaction may be due to differences
in conformation ofp74-88 when bound to Ab vs. Abm-12MHC
molecules cannot be dismissed.
Characterization of the ap TCRs of B6 and bm-12 T-Cefl
Clones. To determine the structural basis for the ligand
specificity of these T-cell clones, we analyzed their TCR a
and p3 chains. We first isolated the rearranged genomic
fragments containing the functional VaJa and VDJ(3 exons
from T-cell hybrid B04H9.1. The nucleotide sequence of
these V regions showed that the P and a chains, respectively,
contained the VP3 and a member of the Vall subfamily
(Figs. 1 and 2). This Va segment, referred to as Vall.b, is
identical to the Vall.3 segment derived from B1O.A mice
(31), except for nine nucleotide substitutions that result in
two amino acid replacements at positions -20 and 43 of the
precursor polypeptide. Because these TCRs were derived
from the B6 strain, it is not clear whether this Va segment is
allelic to Vall.3 of B10 mice or whether it is a member of the
Vall subfamily (39). The V,83 and Vall.b fragments were
used to screen Northern blots of nine B6 and eight bm-12
T-cell clones to identify other TCRs that also expressed these
two V gene segments. From this analysis, one additional B6
(BO3H.25) and two bm-12 (bm2T3.1 and bm4T6.2) T-cell
clones were identified that expressed transcripts hybridizing
with both the Vf3 and Vall.b probes (see Fig. 2). By
sequence analysis of rearranged genomic fragments, we also
determined that B04T27.6, bmlT7.6, and bm4T17.2 TCRs
contained the Vf36, V32, and Vf33 gene segments, respec-
tively (Fig. 2 and data not shown). Interestingly, the
bm4T17.2TCR contained the Va3 gene segment showing that
the VP3-bearing 8 chains could alternatively pair with a
chains bearing either Vall.bm or Va3 segments (Fig. 2). To
facilitate identification of functionally significant residues,
we characterized the subset of TCRs that shared identical
V,33 and closely related Vall segments in detail.
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B -20 -10 .1 .0 .M +.a +40 .6 40 +70 .6
*
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Vall.G8 .....S...........................................
Val1.2
.......................................................00 ................................
Vall.3 .E...............S..K.K. ...N. ..SIAATT ....LO.P... ..VP. S.
Val1.b S..K.K. ...N.. SIAATT ....LQ.P. VP. S.
Vall.bmn .E.SP.T. ..L.L.PL.NP ...MP ..P Y..AE.G. ..s.KG... .0 .R...0. T.N ...........K
FIG. 1. (A) Nucleotide and deduced amino acid sequences of coding regions from TCR a chain genes of B04H9.1 and bm2T3.1 T cells. The
boundary between the N region and Ja is based on germ-line sequences ofJa33 (28) and Jal8 (B. Koop, R. Wilson, and L.H., unpublished data)
for B04H9.1 and bm2T3.1 cell lines, respectively. (B) Members of the Vall subfamily. The predicted location of the cleavage site (*) of the
leader peptide is based on the rules of von Heijne (29). In A and B, dots indicate sequence identity to the top sequence and dashes indicate lack
of that residue in either sequence. Sequences of Vall.l and Vall.2 (9, 10, 30), Vall.3 (31), and Vall.G8 (32) are from the indicated reference.
Sequence data of functional TCR a and (3 chain genes
isolated from B04H9.1, B03H.25, bm2T3.1, bm4T6.2, and
bm4T17.2 cells are shown in Figs. 1A and 2. Comparison of
the nucleotide and deduced primary sequence of a chain
cDNA clones isolated from bm2T3.1 and bm4T6.2 T cells
showed that both TCRs utilized an identical Va gene segment
(Fig. 1B, sequence Vall.bm). Each of the independently
isolated Vall.b and Vall.bm members was identical in their
nucleotide sequences, consistent with lack of somatic hyper-
mutation among TCR genes. Comparison of the Vall.bm
sequence with other members of the Vall subfamily shows
that this segment shares 70-80% similarity with either
Vall.l/.2 or Vall.3/.b segments at either nucleotide or
amino acid levels (Fig. 1B).
Comparison of nucleotide and predicted amino acid se-
quences encoding Va and V(3 chains expressed by the B6 and
bm-12 clones showed that these TCRs are closely related
(Figs. 1A and 2). Despite the fact that each of these T cells
was isolated from different mice, BO3H.25 and B04H9.1
TCRs contained identical Vall.b segments joined to Ja33,
with only a single Ala -* Gly substitution at the Va-Ja
junction. Similarly, bm2T3.1 and bm4T6.2 TCRs used the
same Vall.bm and Jal8 segments with only three residue
differences (Glu-Ala-Asp to Asp-Met-Asn) at the Va-Ja
junction. Each TCR contained the same VB3 segment with
differences localized only to the JP and VDJ,8 junctions.
Again, both B6- and bm-12-derived TCRs used either the
J,81.2 or the Jp2.6 gene segments. Furthermore, both bm-12
TCRs used identical ( chain polypeptides despite nucleotide
sequence differences at the V-J junction. All three V,833
bm-12 TCRs used the same Jj32.6 segment. The repeated
usage of the same J13 segments suggests that they serve an
important function in determining the ligand specificity of
these TCRs.
How do these af3 TCRs recognize the peptide-MHC com-
plex? Among these two B6 and bm-12 sets of T cells, each
specific for the same antigen p74-88 bound to either Ab or
Abm-12 MHC molecules, at least five pairs of a and ,8 chains
were expressed. Distinct TCR a and ,3 chain pairs that
recognize the same peptide-MHC complex can be thought to
bind the antigen-MHC ligand by three mechanisms. (i)
Despite their apparent similarity, the antigen-MHC ligands
--
-Va -- -----N----- ------ Ja-- --- - ---- VP---- ----- DO - JO---
A E
BO4H9.1 GCT GAG
G E
803H25 GGG GAG
V E
bm2T3.1 GTT GA G
V D
bm4T6.2 GTT GA T
V S
bm4T17.2 GTG AGC
D T G N
G AT ACA GGA AAC
D T G N
G AT ACA GGA AAC
A D
GCG GAC
N
A TG
A H
GCG C AT
Y N
TAT AAC
N Y N
AAT TAT AAC
G N E
GGA AAT GAG
S S L M G N
AGC AGT CTG ATG GGG AA
S S L F G T
AGC AGT CTG TTC GGG AC
S S R D F
AGC AGT C GG GAC TTT
S S R D F
AGC AGT C GG GAC TT
S S R G S
AGC AGT C GG GGG AG
S D
C TCC GAC
S D
C TCC GAC
Y E
TAT GAA
Val1 .b-Ja33/VP3-J1 .2
Va11.b-Ja33/Vp3-Jo1 .2
Val1.bfn-Jal8/VP3-JO2.6
Y E
C TAT GAA Va11.bm-Ja18/VO3-JB2.6
S Y
C TCC TAT Va3-Ja40/VP3-J#2.6
FIG. 2. B6 and bm-12 TCR a and p chain nucleotide and amino acid sequences at the V-J junctions. In the absence of available germ-line
sequence for Vall.b and Vall.bm, the Va-N boundary is shown with the last two codons of the Va segment based on comparison to Vall.1
and Vall.2 (33). The 3' boundary of VB3 segment is based on germ-line sequence (34). The /3 chain cDNA sequence for BO3H.25 is identical
to the published genomic sequence (34). The N-J boundaries were determined by comparison to the germ-line sequences of Ja33 (28), Jal8 and
Ja4O (B. Koop, R. Wilson, and L.H., unpublished data), JP1.2 (35), and J,82.6 (36). The N regions for the ,8 chains are indicated under the D.8
heading with the D3,81 (37) or D132 (38) germ-line sequences underlined.
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may be quite different. For example, the same p74-88 may
bind to the antigen binding groove of the MHC molecules in
more than one conformation and thus give rise to distinct
ligand structures as hypothesized for the p52-61-Ak complex
(27). (ii) Even if a single stable conformation ofp74-88-MHC
ligand exists, the TCRs may bind to distinct surfaces of the
same ligand. In this context, it is interesting that different
nonapeptides bound to the antigen binding site of human
HLA-B27 class I MHC molecules appear to occupy a fixed
orientation (40). Whether the generally larger peptides such
as the 15-residue p74-88 described here and those recently
eluted from class II MHC molecules (41) will also occupy
similar fixed positions within the antigen binding groove of
class II MHC molecules is not known. (iii) A single ligand
may be recognized by the TCRs in a similar orientation, and
the combining sites formed by the distinct a and P chains may
in fact be functionally equivalent. The first two possibilities
predict that differences in af3 TCR structure are due to their
different ligand specificities, whereas the third possibility
predicts that, despite different primary sequences, function-
ally equivalent TCR combining sites may be generated. These
three possibilities cannot be distinguished by sequence com-
parisons alone but are amenable to experimental test (42).
Interestingly, four TCRs from B6 (BO3H.25 and B04H9.1)
and bm-12 (bm2T3.1 and bm4T6.2) mice expressed the same
V,33 segment with two members of the Vall subfamily. Fur-
thermore, both pairs of B6 TCRs used the same JP1.2 and Ja33
segments and the bm-12 TCRs expressed the J/82.6 and Jal8
segments. The repeated occurrence of these segments in the
TCRs is unlikely to be fortuitous because these TCRs were
independently isolated. Also, these particular combinations of
gene segments were not found among the random set of 178 B6
TCRs alloreactive to the Abm-l2 MHC molecules (43). The
differences in ligand specificity of these TCRs must, therefore,
be accounted for by amino acid differences within V(-Jf3junctions and a polypeptides. Extensive analysis of V segment
usage among cytochrome-specific TCRs has shown that ex-
pression of Vall.1 or Vall.2 segments with alternative Vf8
segments correlates strongly with recognition of the cy-
tochrome peptide by different alleles of the E class II MHC
molecule (6, 9). However, the fact that our TCRs clearly
distinguish the Ab vs. Abm-l2 molecules and yet use identical
V/33 segments shows that V13 segments do not by themselves
play a major role in determining peptide or MHC (8 chain
specificity of the TCRs. Instead our results point to the impor-
tance of other regions of a and (3 chains in determining ligand
specificity.
Current models of TCR-ligand interactions suggest that con-
tacts between the TCR and the MHC molecule primarily occur
within residues of Va and VB segments, whereas residues
within Ja, JP3, and junction regions contact the peptide antigen(5, 13). Because the antigenic peptides recognized by all our
TCRs are similar, application of these models to our TCRs
predicts that differences within the Vall.b and Vall.bm seg-
ments would be associated with recognition of the MHC-
specific differences. The Vall.b and Vall.bm segments of the
mature polypeptides differ in 24 out of a total of 87 amino acids.
Fourteen ofthese residues occur within the first 30 amino acids,
and a contiguous cluster of 5 amino acid substitutions occurs at
residues 26-30. Significantly, residues 28-34 and 31-35 of the
antibody light and heavy chains, respectively, contain the first
CDR region. Thus, it is attractive to postulate that this cluster
defines one of the CDR regions of the Va segments. However,
the importance of this cluster and of other regions of the TCR
in determining the peptide-MHC specificity must await results
of mutagenesis experiments.
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